サンプル依頼リスト カート
  • English
  • Korean
表紙：骨髄異形成症候群の世界市場レポート 2024年
市場調査レポート
商品コード
1415667

骨髄異形成症候群の世界市場レポート 2024年

Myelodysplastic Syndrome Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
骨髄異形成症候群の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

骨髄異形成症候群の市場規模は近年急速に拡大しています。2023年の23億米ドルから2024年には25億6,000万米ドルへ、CAGR11.5％で成長します。実績期間の成長は、骨髄異形成症候群の有病率の増加、骨髄異形成症候群治療に対する意識の高まり、ヘルスケア支出の増加、政府の取り組みに起因しています。

骨髄異形成症候群の市場規模は今後数年で急成長が見込まれます。2028年にはCAGR10.2％で37億8,000万米ドルに成長します。予測期間の成長は、高齢化、併用療法の採用、血液学的研究への投資、個別化医療に起因しています。予測期間の主な動向には、骨髄異形成症候群の革新的治療、診断ツールや技術の進歩、臨床試験、共同研究などが含まれます。

骨髄異形成症候群（MDS）市場は、希少血液がんの罹患率上昇に牽引され、成長する見込みです。血液悪性腫瘍に分類されるこれらの稀な血液がんは、集団内での発生率が低く、骨髄、リンパ節、血液および免疫系の他の要素の細胞から発生します。MDSの治療は、骨髄における血液がんの進行を防ぐために、病状の管理、血球産生の改善、関連症状への対処が中心となります。例えば、オーストラリアの慈善団体である白血病財団は、2021年6月現在、11万人以上が血液疾患と闘っていると報告しています。さらに、2035年までに血液疾患に罹患するオーストラリア人の数は275,000人を超えると予想されています。したがって、血液がんの有病率の増加が骨髄異形成症候群（MDS）市場成長の原動力となっています。

骨髄異形成症候群（MDS）市場は、骨髄移植件数の急増が予想されることから、拡大が見込まれています。骨髄移植は、さまざまな症状を治療するために、損傷または病気の骨髄を健康な幹細胞と置き換える医療処置です。MDSは、体細胞変異を起こした造血幹細胞のクローン性増殖によって起こる骨髄不全を特徴とします。骨髄移植は、異常な幹細胞を健康な幹細胞に置き換えることで、MDSに効果的に対処することができます。例えば、米国政府機関であるHealth Resources and Services Administrationのデータによると、2021年には米国で合計5,073件の非血縁者と4,276件の血縁者の骨髄および臍帯血移植が実施され、国際血液骨髄移植研究センター（CIBMTR）に報告されました。その結果、骨髄異形成症候群市場の成長は、主に骨髄移植の増加によって促進されています。

2023年の骨髄異形成症候群市場では北米が最大地域でした。骨髄異形成症候群（MDS）レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の骨髄異形成症候群市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 単系統異形成を伴う骨髄異形成症候群
  • 多系統異形成を伴う骨髄異形成症候群
  • 環状鉄芽球を伴う骨髄異形成症候群
  • その他のタイプ
  • 世界の骨髄異形成症候群市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アザシチジン
  • レナリドミド
  • デシタビン
  • デフェラシロクス
  • 世界の骨髄異形成症候群市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 支持療法
  • 成長因子
  • 化学療法
  • 幹細胞移植
  • その他
  • 世界の骨髄異形成症候群市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 注射
  • その他
  • 世界の骨髄異形成症候群市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 病院
  • ホームケア
  • 専門センター
  • その他

第7章 地域および国の分析

  • 世界の骨髄異形成症候群市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の骨髄異形成症候群市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 骨髄異形成症候群市場の競合情勢
  • 骨髄異形成症候群市場企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Limited
    • AbbVie Inc.
    • Bayer AG
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Merck & Co.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Company Limited
  • Medtronic Plc
  • Eli Lilly and Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Otsuka Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company Ltd.
  • Jazz Pharmaceuticals
  • Dr. Reddy's Laboratories Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12266

“Myelodysplastic Syndrome Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelodysplastic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelodysplastic syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The myelodysplastic syndrome market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Myelodysplastic Syndrome With Unilineage Dysplasia; Myelodysplastic Syndrome With Multilineage Dysplasia; Myelodysplastic Syndrome With Ring Sideroblasts; Other Types
  • 2) By Drug: Azacitidine; Lenalidomide; Decitabine; Deferasirox
  • 3) By Treatment: Supportive Therapy; Growth Factors; Chemotherapy; Stem Cell Transplant; Other Treatments
  • 4) By Route Of Administration: Oral; Injectable; Other Routes Of Administrations
  • 5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; AbbVie Inc.; Bayer AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Myelodysplastic syndrome (MDS) encompasses a group of conditions characterized by the aberrant development and functioning of bone marrow cells, leading to inefficient production of blood cells. Treatment for myelodysplastic syndrome is aimed at enhancing blood cell counts, alleviating associated symptoms, and retarding the progression of the disease. It's noteworthy that myelodysplastic syndrome (MDS) can evolve into acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Within the spectrum of myelodysplastic syndrome, various subtypes exist, including myelodysplastic syndrome with unilineage dysplasia, myelodysplastic syndrome with multilineage dysplasia, and myelodysplastic syndrome with ring sideroblasts. Myelodysplastic syndrome (MDS) with unilineage dysplasia is a specific classification within the range of MDS conditions. Treatment options for myelodysplastic syndrome encompass a range of drugs such as azacitidine, lenalidomide, decitabine, and deferasirox. Various treatment modalities are employed, including supportive therapy, growth factors, chemotherapy, and stem cell transplantation. These treatments can be administered through multiple routes, including oral, injectable, and others, and are delivered in diverse healthcare settings, such as hospitals, homecare, specialty centers, and more.

The myelodysplastic syndrome market research report is one of a series of new reports from The Business Research Company that provides myelodysplastic syndrome market statistics, including myelodysplastic syndrome industry global market size, regional shares, competitors with a myelodysplastic syndrome market share, detailed myelodysplastic syndrome market segments, market trends and opportunities and any further data you may need to thrive in the myelodysplastic syndrome industry. This myelodysplastic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myelodysplastic syndrome market size has grown rapidly in recent years. It will grow from $2.3 billion in 2023 to $2.56 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing prevalence of myelodysplastic syndrome, growing awareness about myelodysplastic syndrome treatment, rising healthcare spending, government initiatives.

The myelodysplastic syndrome market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to aging population, adoption of combination therapies, investment in hematologic research, personalized medicine. Major trends in the forecast period include innovative treatments for myelodysplastic syndrome, advancements in diagnostic tools and techniques, clinical trials, collaborative research.

The myelodysplastic syndrome (MDS) market is poised for growth, driven by the rising incidence of rare blood cancers. These uncommon blood cancers, categorized as hematologic malignancies, have a low occurrence rate within the population and originate in the cells of the bone marrow, lymph nodes, and other elements of the blood and immune system. MDS treatment is centered on managing the condition, improving blood cell production, and addressing related symptoms to prevent the progression of blood cancer in the bone marrow. For example, the Leukemia Foundation, a charitable organization in Australia, reported that more than 110,000 individuals are currently grappling with blood disorders as of June 2021. Moreover, it is anticipated that by 2035, the number of Australians affected by blood disorders will surpass 275,000. Hence, the increasing prevalence of blood cancers is a driving force behind the growth of the myelodysplastic syndrome (MDS) market.

The myelodysplastic syndrome (MDS) market is poised for expansion, driven by the expected surge in the number of bone marrow transplants. Bone marrow transplants are medical procedures in which damaged or diseased bone marrow is replaced with healthy stem cells to treat various conditions. MDS is characterized by bone marrow failure, which occurs due to the clonal expansion of somatically mutated hematopoietic stem cells. Bone marrow transplantation can effectively address MDS by replacing aberrant stem cells with healthy ones. For example, in 2021, a total of 5,073 unrelated and 4,276 related bone marrow and cord blood transplants were conducted in the United States and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR), as per data from the Health Resources and Services Administration, a US-based government agency. Consequently, the growth of the myelodysplastic syndrome market is being primarily fueled by the increasing number of bone marrow transplants.

The elevated expenses linked to myelodysplastic syndrome treatment can have a profound effect on the growth of the myelodysplastic syndrome (MDS) market, potentially limiting patient access and impeding overall market expansion. For instance, a report published by Springer Nature Group in November 2022 revealed that treatment costs have been notably high, particularly with regards to transfusions. In fact, these transfusions accounted for 81.3% of supportive care costs for patients transitioning to acute myeloid leukemia (AML) and 65.7% of supportive care costs. Consequently, the high cost of myelodysplastic syndrome treatment is posing a challenge to the market's growth.

Prominent companies within the myelodysplastic syndrome (MDS) market are dedicated to pioneering novel treatments to fortify their market presence. For instance, in July 2021, Genentech Inc., a US-based biotechnology firm, introduced Venclexta (venetoclax) in conjunction with azacitidine for the treatment of myelodysplastic syndrome (MDS) following approval from the US Food and Drug Administration (FDA). This approval encompasses the treatment of adult patients diagnosed with intermediate, high-risk, and very high-risk myelodysplastic syndromes (MDS). This groundbreaking therapy aims to expedite the development of medications intended to address severe or life-threatening conditions, with preliminary data suggesting substantial enhancements compared to existing treatments.

In November 2021, Merck & Co. Inc., a US-based pharmaceutical company, acquired Acceleron Pharma Inc. for an undisclosed amount. With this acquisition, Merck & Co. Inc. aims to expand its cardiovascular portfolio and further strengthen its commercial development strategy, addressing the urgent medical need to reach even more patients. Acceleron Pharma Inc. is a US-based clinical-stage biopharmaceutical company that develops medicines for myelodysplastic syndrome (MDS).

Major players in the myelodysplastic syndrome market are Pfizer Inc., Johnson and Johnson Limited, AbbVie Inc., Bayer AG, Novartis AG, Merck & Co., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Company Limited, Medtronic PLC, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Jazz Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Lupin Limited, BeiGene, Janssen Biotech, Accord Healthcare, Acceleron Pharma Inc.

North America was the largest region in the myelodysplastic syndrome market in 2023. The regions covered in myelodysplastic syndrome (MDS) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelodysplastic syndrome (MDS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelodysplastic syndrome (MDS) market consists of revenues earned by entities by providing experimental therapies, targeted therapies and blood transfusion. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelodysplastic syndrome (MDS) market also consists of sales of erythropoiesis-stimulating agents (ESAs) and immunomodulatory drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Myelodysplastic Syndrome Market Characteristics

3. Myelodysplastic Syndrome Market Trends And Strategies

4. Myelodysplastic Syndrome Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Myelodysplastic Syndrome Market Size and Growth

  • 5.1. Global Myelodysplastic Syndrome Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Myelodysplastic Syndrome Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Myelodysplastic Syndrome Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myelodysplastic Syndrome Market Segmentation

  • 6.1. Global Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Myelodysplastic Syndrome With Unilineage Dysplasia
  • Myelodysplastic Syndrome With Multilineage Dysplasia
  • Myelodysplastic Syndrome With Ring Sideroblasts
  • Other Types
  • 6.2. Global Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Azacitidine
  • Lenalidomide
  • Decitabine
  • Deferasirox
  • 6.3. Global Myelodysplastic Syndrome Market, Segmentation By Treatment , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Supportive Therapy
  • Growth Factors
  • Chemotherapy
  • Stem Cell Transplant
  • Other Treatments
  • 6.4. Global Myelodysplastic Syndrome Market, Segmentation By Route Of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • Other Routes Of Administrations
  • 6.5. Global Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Speciality Centres
  • Other End-Users

7. Myelodysplastic Syndrome Market Regional And Country Analysis

  • 7.1. Global Myelodysplastic Syndrome Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Myelodysplastic Syndrome Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myelodysplastic Syndrome Market

  • 8.1. Asia-Pacific Myelodysplastic Syndrome Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myelodysplastic Syndrome Market

  • 9.1. China Myelodysplastic Syndrome Market Overview
  • 9.2. China Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myelodysplastic Syndrome Market

  • 10.1. India Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myelodysplastic Syndrome Market

  • 11.1. Japan Myelodysplastic Syndrome Market Overview
  • 11.2. Japan Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myelodysplastic Syndrome Market

  • 12.1. Australia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myelodysplastic Syndrome Market

  • 13.1. Indonesia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myelodysplastic Syndrome Market

  • 14.1. South Korea Myelodysplastic Syndrome Market Overview
  • 14.2. South Korea Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myelodysplastic Syndrome Market

  • 15.1. Western Europe Myelodysplastic Syndrome Market Overview
  • 15.2. Western Europe Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myelodysplastic Syndrome Market

  • 16.1. UK Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myelodysplastic Syndrome Market

  • 17.1. Germany Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myelodysplastic Syndrome Market

  • 18.1. France Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myelodysplastic Syndrome Market

  • 19.1. Italy Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myelodysplastic Syndrome Market

  • 20.1. Spain Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myelodysplastic Syndrome Market

  • 21.1. Eastern Europe Myelodysplastic Syndrome Market Overview
  • 21.2. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myelodysplastic Syndrome Market

  • 22.1. Russia Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myelodysplastic Syndrome Market

  • 23.1. North America Myelodysplastic Syndrome Market Overview
  • 23.2. North America Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myelodysplastic Syndrome Market

  • 24.1. USA Myelodysplastic Syndrome Market Overview
  • 24.2. USA Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myelodysplastic Syndrome Market

  • 25.1. Canada Myelodysplastic Syndrome Market Overview
  • 25.2. Canada Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myelodysplastic Syndrome Market

  • 26.1. South America Myelodysplastic Syndrome Market Overview
  • 26.2. South America Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myelodysplastic Syndrome Market

  • 27.1. Brazil Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myelodysplastic Syndrome Market

  • 28.1. Middle East Myelodysplastic Syndrome Market Overview
  • 28.2. Middle East Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myelodysplastic Syndrome Market

  • 29.1. Africa Myelodysplastic Syndrome Market Overview
  • 29.2. Africa Myelodysplastic Syndrome Market, Segmentation By Type , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Myelodysplastic Syndrome Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Myelodysplastic Syndrome Market, Segmentation By End-Users , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myelodysplastic Syndrome Market Competitive Landscape And Company Profiles

  • 30.1. Myelodysplastic Syndrome Market Competitive Landscape
  • 30.2. Myelodysplastic Syndrome Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bayer AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Myelodysplastic Syndrome Market Other Major And Innovative Companies

  • 31.1. Merck & Co.
  • 31.2. Sanofi S.A.
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. AstraZeneca Plc.
  • 31.5. Takeda Pharmaceutical Company Limited
  • 31.6. Medtronic Plc
  • 31.7. Eli Lilly and Company
  • 31.8. Amgen Inc.
  • 31.9. Boehringer Ingelheim International GmbH
  • 31.10. Otsuka Pharmaceutical Co. Ltd.
  • 31.11. Teva Pharmaceutical Industries Ltd.
  • 31.12. Astellas Pharma Inc.
  • 31.13. Daiichi Sankyo Company Ltd.
  • 31.14. Jazz Pharmaceuticals
  • 31.15. Dr. Reddy's Laboratories Ltd.

32. Global Myelodysplastic Syndrome Market Competitive Benchmarking

33. Global Myelodysplastic Syndrome Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Market

35. Myelodysplastic Syndrome Market Future Outlook and Potential Analysis

  • 35.1 Myelodysplastic Syndrome Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Myelodysplastic Syndrome Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Myelodysplastic Syndrome Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer